COMPASS Pathways (CMPS) Stock Forecast, Price Target & Predictions
CMPS Stock Forecast
COMPASS Pathways stock forecast is as follows: an average price target of $23.00 (represents a 263.35% upside from CMPS’s last price of $6.33) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
CMPS Price Target
CMPS Analyst Ratings
COMPASS Pathways Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jul 22, 2024 | Leonid Timashev | RBC Capital | $23.00 | $7.43 | 209.56% | 263.35% |
Jun 05, 2024 | Vikram Purohit | Morgan Stanley | $23.00 | $6.70 | 243.29% | 263.35% |
COMPASS Pathways Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 1 | 2 |
Avg Price Target | - | $23.00 | $23.00 |
Last Closing Price | $6.33 | $6.33 | $6.33 |
Upside/Downside | -100.00% | 263.35% | 263.35% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Jul 22, 2024 | RBC Capital | - | Outperform | Initialise |
Jun 05, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
Apr 01, 2024 | Morgan Stanley | - | Overweight | Initialise |
Oct 13, 2022 | Oppenheimer | Outperform | Outperform | Hold |
COMPASS Pathways Financial Forecast
COMPASS Pathways Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
COMPASS Pathways EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
COMPASS Pathways Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-36.01M | $-36.24M | $-34.87M | $-38.52M | $-39.16M | $-38.99M | $-36.83M |
High Forecast | $-36.01M | $-36.24M | $-34.87M | $-38.52M | $-39.16M | $-32.49M | $-36.83M |
Low Forecast | $-36.01M | $-36.24M | $-34.87M | $-38.52M | $-39.16M | $-44.19M | $-36.83M |
Surprise % | - | - | - | - | - | - | - |
COMPASS Pathways SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
COMPASS Pathways EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-0.53 | $-0.53 | $-0.51 | $-0.56 | $-0.57 | $-0.57 | $-0.54 |
High Forecast | $-0.53 | $-0.53 | $-0.51 | $-0.56 | $-0.57 | $-0.48 | $-0.54 |
Low Forecast | $-0.53 | $-0.53 | $-0.51 | $-0.56 | $-0.57 | $-0.65 | $-0.54 |
Surprise % | - | - | - | - | - | - | - |
COMPASS Pathways Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
CMPS | COMPASS Pathways | $6.31 | $23.00 | 264.50% | Buy |
CCRN | Cross Country Healthcare | $12.02 | $21.00 | 74.71% | Buy |
AGL | agilon health | $2.81 | $4.88 | 73.67% | Buy |
ACHC | Acadia Healthcare Company | $53.16 | $82.33 | 54.87% | Buy |
AMED | Amedisys | $97.40 | $143.38 | 47.21% | Hold |
EHAB | Enhabit | $7.18 | $10.25 | 42.76% | Hold |
SGRY | Surgery Partners | $31.88 | $44.33 | 39.05% | Buy |
INNV | InnovAge | $5.82 | $6.80 | 16.84% | Hold |
ADUS | Addus HomeCare | $130.95 | $129.40 | -1.18% | Buy |
PNTG | Pennant Group | $32.85 | $30.67 | -6.64% | Buy |
ENSG | Ensign Group | $147.72 | $131.20 | -11.18% | Buy |
DVA | DaVita | $161.54 | $125.50 | -22.31% | Hold |
CMPS Forecast FAQ
Is COMPASS Pathways a good buy?
Yes, according to 3 Wall Street analysts, COMPASS Pathways (CMPS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of CMPS's total ratings.
What is CMPS's price target?
COMPASS Pathways (CMPS) average price target is $23 with a range of $23 to $23, implying a 263.35% from its last price of $6.33. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will COMPASS Pathways stock go up soon?
According to Wall Street analysts' prediction for CMPS stock, the company can go up by 263.35% (from the last price of $6.33 to the average price target of $23), up by 263.35% based on the highest stock price target, and up by 263.35% based on the lowest stock price target.
Can COMPASS Pathways stock reach $9?
CMPS's average twelve months analyst stock price target of $23 supports the claim that COMPASS Pathways can reach $9 in the near future.
What are COMPASS Pathways's analysts' financial forecasts?
COMPASS Pathways's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-115M (high $-108M, low $-120M), average SG&A $0 (high $0, low $0), and average EPS is $-1.682 (high $-1.587, low $-1.758). CMPS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-146M (high $-146M, low $-146M), average SG&A $0 (high $0, low $0), and average EPS is $-2.13 (high $-2.13, low $-2.13).